Cell engineering combines gene editing, stem cell biology, and regenerative medicine to create therapeutic cells with enhanced or entirely new functions. This field encompasses CAR-T cell therapy for cancer, iPSC-derived cell therapies, organoid models for drug testing, and xenotransplantation of gene-edited pig organs into humans. With multiple FDA-approved CAR-T products and an expanding pipeline of stem cell-based therapies, cell engineering represents the convergence of gene editing technology with cellular biology to create living medicines.
Engineering T cells with chimeric antigen receptors to recognize and kill cancer
Reprogramming adult cells to pluripotent stem cells for patient-specific therapies
Miniature 3D organ models grown from stem cells for disease research and drug testing
Transplanting CRISPR-edited animal organs into human recipients
Understanding and engineering the microenvironments that maintain stem cells
Blood-forming stem cells targeted by gene therapies for blood disorders
In-depth analysis and expert-level coverage
Accessible introductions for newcomers
An accessible guide to CAR-T cell therapy -- how scientists collect, engineer, and infuse a patient's own immune cells to fight cancer, and where the field is headed next.
How scientists grow miniature versions of human organs from stem cells, and why these tiny structures are transforming drug testing, disease modeling, and personalized medicine.
Using 3D printing technology to deposit living cells, biomaterials, and growth factors layer by layer to fabricate tissue-like structures. An emerging approach in regenerative medicine for creating transplantable tissues and organs.
An early embryonic stage (around day 5-6 post-fertilization) containing an outer trophoblast layer and an inner cell mass. Embryonic stem cells are derived from the inner cell mass of a blastocyst.
The process by which an unspecialized cell (such as a stem cell) becomes a specialized cell type with distinct structure and function. Directed differentiation of iPSCs is the foundation of regenerative medicine.
The process by which a stem cell becomes a specialized cell type (neuron, blood cell, muscle cell, etc.). Directed differentiation of gene-edited iPSCs is a key strategy for creating cell therapies.
ESC — a pluripotent stem cell derived from the inner cell mass of a blastocyst, capable of differentiating into any cell type of the body. First isolated in humans by Thomson in 1998.
One of three foundational tissue layers (endoderm, mesoderm, ectoderm) formed during gastrulation from which all adult tissues develop. Pluripotency is defined by the ability to form cells of all three germ layers.
HSC — a multipotent stem cell in bone marrow that gives rise to all blood and immune cell lineages. Target of many gene therapies including Casgevy (sickle cell) and gene-edited CAR-T.
Hematopoietic Stem and Progenitor Cells — blood-forming stem cells found in bone marrow that give rise to all blood cell types. The target cells for gene therapies treating blood disorders like sickle cell disease, beta-thalassemia, and severe combined immunodeficiency.
Induced Pluripotent Stem Cells — adult cells reprogrammed back to an embryonic-like state using Yamanaka factors (Oct4, Sox2, Klf4, c-Myc). Discovered by Shinya Yamanaka in 2006 (Nobel Prize 2012). Can differentiate into any cell type, enabling patient-specific disease models and cell therapies without embryonic tissue.
Multipotent stem cells that can differentiate into bone, cartilage, fat, and muscle cells. Found in bone marrow, fat tissue, and umbilical cord blood. Widely studied for regenerative medicine, though clinical evidence for many uses remains limited.
A stem cell that can differentiate into multiple but limited cell types within a single lineage, such as hematopoietic stem cells giving rise to all blood cells.
Miniature 3D organ models grown from stem cells in the lab. Recapitulate the architecture and function of real organs (brain, gut, liver, kidney). Used to study disease, test drugs, and model gene editing effects before clinical use.
The ability of a stem cell to develop into any cell type in the body. Embryonic stem cells and iPSCs are pluripotent. Partial reprogramming aims to reset the epigenetic clock without full pluripotency to avoid tumor risk.
The ability of a stem cell to differentiate into any of the three germ layers (endoderm, mesoderm, ectoderm) and thus any adult cell type. Embryonic stem cells and iPSCs are pluripotent.
The local microenvironment (supporting cells, extracellular matrix, soluble factors) that maintains stem cell identity, self-renewal, and differentiation. Niche dysfunction contributes to stem cell exhaustion in aging.
| Therapy | Company | Disease | Phase | Status |
|---|---|---|---|---|
| Kymriah (tisagenlecleucel) | Novartis | B-cell acute lymphoblastic leukemia (ALL) & diffuse large B-cell lymphoma (DLBCL) | Approved | Approved |
| Yescarta (axicabtagene ciloleucel) | Gilead Sciences / Kite Pharma | Diffuse large B-cell lymphoma (DLBCL) | Approved | Approved |
| Tecartus (brexucabtagene autoleucel) | Gilead Sciences / Kite Pharma | Mantle cell lymphoma (MCL) | Approved | Approved |
| Breyanzi (lisocabtagene maraleucel) | Bristol Myers Squibb | Large B-cell lymphoma (LBCL) | Approved | Approved |
| Abecma (idecabtagene vicleucel) | Bristol Myers Squibb / 2seventy bio | Relapsed/refractory multiple myeloma | Approved | Approved |
| Carvykti (ciltacabtagene autoleucel) | Johnson & Johnson / Legend Biotech | Relapsed/refractory multiple myeloma | Approved | Approved |
| CT041 (Satricabtagene autoleucel) | CARsgen Therapeutics | Gastric / gastroesophageal junction cancer | Phase 2 | Active |
| NexCAR19 (actalycabtagene autoleucel) | ImmunoACT / IIT Bombay | B-cell acute lymphoblastic leukemia (ALL) | Approved | Approved |
| Equecabtagene Autoleucel (Fucaso) | IASO Bio / Innovent Biologics | Relapsed/refractory multiple myeloma | Approved | Approved |
| Yescarta China (FKC876) | Fosun Kite Biotechnology | Relapsed/refractory large B-cell lymphoma | Approved | Approved |
